VirtualScopics — Shareholder Meeting (May 2008)
27 slides from VirtualScopics's shareholder meeting presentation, May 8, 2008
Slide 1: Annual Stockholders' Meeting Company Overview
Exhibit 99.2 d VIRTUALSCOPICS Know more. Move faster. Annual Stockholders’ Meeting Company Overview May 8, 2008 ¥ VIRTUALSCOPICS Quantitative Imaging for Clinical Trials
Slide 2: Safe Harbor
Safe Harbor This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achie
Slide 3: Business Overview
Business Overview ¢ Recap from 2007 Annual Meeting ¢ The Company — History — Value proposition to the pharmaceutical industry — Achievements ¢ Financial Overview — 1% Quarter 2008 results — Historical view of the Company's progress ¢ Financial markets and stock price ¥ VIRTUALSCOPICS Quantitative Im
Slide 4: Major Focus Going Forward
Major Focus Going Forward (From May 22, 2007 Annual Meeting) « New Customer Agreements — Scaling of the sales force — Later stage trials — Emphasis on oncology ¢ Operational Scale — Efficiency — Repeatability — Customer service/focus « Research and Development — Peer reviewed journal publishing — Se
Slide 5: Major Focus Going Forward: Results
Major Focus Going Forward (Presented at May 22,2007 Annual Meeting) RESULT: ¢ Greater than 80% growth in awards of new contracts « Doubled the size of our sales force and opened a European sales Office * 2007 63% of new contract awards represent later phase trials * Oncology represented over 60% whi
Slide 6: Major Focus Going Forward: Results
Major Focus Going Forward (Presented at May 22, 2007 Annual Meeting) RESULT: + Revenue and project load up 15% and 10% respectively in Q1 2008 vs. Q4 2007 with 15% less people « Implementation of lean methodology reduced project setup time by 50% + Customer Service: ‘twas asked by management fo do a
Slide 7: Major Focus Going Forward: Results
Major Focus Going Forward (Presented at May 22,2007 Annual Meeting) RESULT: * 8 Scientific papers published in peer reviewed or industry journals. + Presented or displayed posters, abstracts, and papers at 8 prominent imaging or industry symposiums. + Industry expert panel role where consortia worki
Slide 8: VirtualScopics
VirtualScopics VirtualScopics is the premier provider of quantitative image-based solutions for clinical trials Key Company Highlights — Integrated solution delivered as a series of services that manage imaging trials from inception to data submission. — Highly automated quantitative analysis vs. co
Slide 9: Clinical Trial Operational Structure
Clinical Trial Operational Structure VS pre-2006 « In 2002, VS began as a niche provider of high-end analysis services - Limited market potential — Lack of visibility to the sponsor of the clinical trial « We were essentially the outsourcer to the outsourcer
Slide 10: Clinical Trial Operational Structure
Clinical Trial Operational Structure VS post-2006 « In 2005, VS began developing capabilities to be a ‘full service imaging provider’ to the Pharma industry — Eliminated need for ‘middleman’ and began developing contracts directly with Pharma — Easier/more cost effective for the sponsor — Significan
Slide 11: Value of Services Beyond Image Analysis
Value of Services Beyond Image Analysis Project Revenue Breakdown 25% 40% © Upfront Services mRecurting Services Analysis Services 35% ¢ Image analysis revenues represent approximately 40% of total project value * The remaining 60% are high value services delivered upfront and throughout the study ¥
Slide 12: Solution to Customers
Solution to Customers Professional Training Services: Data Management Analysis Services: = On-site clinician Services: Services: = Imaging modality training = Incoming image = Biomarker selection = Equipment inspection extraction = Biomarker selection assessment = Image and data = Biomarker = Projec
Slide 13: Specific Example - Oncology
Specific Example - Oncology ¢ Estimated 1.4 million new cases were diagnosed in 2007 ¢ NIH estimated the cost of cancer in 2007 to be $250 billion ¢ Mortality rates have declined over the past several years due to improved and targeted therapies ¢ Estimated market for imaging related clinical trial
Slide 14: Structural Imaging in Oncology
Structural Imaging in Oncology Conventional Method -Traditional CT Image * Crude 2D line used to characterize 3D object ¢ New therapy’s work a from inside the tumor so overall length may not change ¢ Additional measures required to characterize response and progression of the disease ¥ VIRTUALSCOPIC
Slide 15: Structural Imaging in Oncology
Structural Imaging in Oncology VirtualScopics Patented Image & Data Analysis ¢ 3D Measures required to characterize 3D objects ° New therapy’s require new techniques ¢ Industry is demanding high precision and sensitivity to change ¥ VIRTUALSCOPICS Quantitative Imaging for Clinical Trials
Slide 16: Structural Imaging in Oncology
Structural Imaging in Oncology 3D Measure New Measure Old measure computed automatically Tumor Label Location 125 TTumort Lier 20056 i) Bi) Tumor2 Adrenal 2054 33500 200 0 2 4160 3780 {Tumor3——_L Lung 38560 20 1210 % 16 560 480 [Tumor Re Lung 33720 20345 15 4 4) 667 565 * Custom analysis designed sp
Slide 17: Pfizer Oncology Study
Pfizer Oncology Study DCE-MRI for tumor functional vascularity Proposed mechanism: Anti-angiogenesis Dynamic contrast enhanced MRI (DCE-MRI) provides a measure of the functioning blood vessels in a tumor. Baseline Day 2 Week 4 Week 8 DCE-MRI showed that a VEGF/PDGF Receptor Tyrosine Kinase Inhibitor
Slide 18: Customer Value
Customer Value « Reduced number of subjects — Higher precision = fewer patients — Fewer patients = lower trial costs * Accelerated time to market — Smaller trial sizes = quicker enrollment and faster results — Algorithm driven analysis yields results faster than radiologists driven analysis ¢ Better
Slide 19: Target Market Forecast
Target Market Forecast Market Size 2007 $490M BMS BAlzheimers OCardiovascular DOA @ RA @ Oncology ¢ Individual markets large and growing rapidly * Oncology and Inflammation are largest individual market areas ¢ Excludes other market opportunities including diagnostics CA a, . . lee ., ¥ VIRTUALSCOPI
Slide 20: Financial Overview
Financial Overview « Review of Q1 2008 results ¢ Historical review of company progression ¢ Update on financial markets YF virruaiscorics Quantitative Imaging for Clinical Trials
Slide 21: Condensed Consolidated Statement of Operations
Condensed Consolidated Statement of Operations (unaudited) ‘Three Months Ended March 31, 2008 2007 Revemmes $ 1634103 $1,278,405 Cost of services 1,029,984 800,519 Gross profit 04119) 477386) Operating expenses: Research andi development, 251,829 06.955 Sales and marketing 288874 213,116 General and
Slide 22: Condensed Consolidated Balance Sheet
Condensed Consolidated Balance Sheet ¥ VIRTUALSCOPICS Assets (Cunnent arsets Cash and cash equivalents Fevtited cash ‘Accounts ceivsble Prepaid expenses and other assets ‘Total quant assets Restricted exh Patets, net Property and equipment wet Other asets Total asset Linhiltine and StockboMens" Equi
Slide 23: Historical Revenues/Customers
Historical Revenues/Customers 6,000 + _ 30 5,000 25 4,000 20 es 8 2 3.000 jg [mm Revenues (r 0005) = — Customers ‘oe a 2,000 40 1,000 5 o 0 2004 2005 2006 2007 ¢ Currently working with 11 of the top 15 pharma/biotechs ° 28 active customers in 2007 vs. 12 in 2004 * 80 active projects in 2007 vs. 35 i
Slide 24: Business Evolution
Business Evolution Contract Awards by Phase/Year 18,000,000 16,000,000, 14,000,000 12,000,000 mPhase Ill 10,000,000 Phase Il 8,000,000 @Phase | GResearch/Pre-clinical 6,000,000 4,000,000 2,000,000 2004 2006 2006 2007 ¢ Prior to 2005, primarily focused on biomarker research and development of an effi
Slide 25: Customer Concentration (2004 vs. 2007)
Customer Concentration (2004 vs. 2007) 2004 2007 28% ° 12 Customers ° 28 Customers ¢ Contracts with 5 of the top 15 = Contracts with 11 of the Pharma/Biotech top 15 Pharma/Biotech ¥ VIRTUALSCOPICS
Slide 26: Financial Markets
Financial Markets ¢ New investor relations firm ¢ Continue to get visibility within the financial markets * Continue to build the business YF virruaiscorics Quantitative Imaging for Clinical Trials
Slide 27: 2008 Focus
2008 Focus ¢ Achievement of financial targets — Revenue growth — Operating cash flow break even ° New Customer Agreements — Replicable projects — Current and expanded customer base ° Operational Scale — Efficiency — Repeatability — Customer service/focus ¢ Progress plans to enter diagnostic market ¥